These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 7651437)

  • 21. p53 DNA binding can be modulated by factors that alter the conformational equilibrium.
    McLure KG; Lee PW
    EMBO J; 1999 Feb; 18(3):763-70. PubMed ID: 9927436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
    Inga A; Monti P; Fronza G; Darden T; Resnick MA
    Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2.
    Thukral SK; Blain GC; Chang KK; Fields S
    Mol Cell Biol; 1994 Dec; 14(12):8315-21. PubMed ID: 7969167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53.
    Dornan D; Shimizu H; Burch L; Smith AJ; Hupp TR
    Mol Cell Biol; 2003 Dec; 23(23):8846-61. PubMed ID: 14612423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in the zinc fingers of ADR1 that change the specificity of DNA binding and transactivation.
    Thukral SK; Morrison ML; Young ET
    Mol Cell Biol; 1992 Jun; 12(6):2784-92. PubMed ID: 1588970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.
    Bargonetti J; Reynisdóttir I; Friedman PN; Prives C
    Genes Dev; 1992 Oct; 6(10):1886-98. PubMed ID: 1398068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of p53 DNA binding activity by point mutation.
    Marston NJ; Ludwig RL; Vousden KH
    Oncogene; 1998 Jun; 16(24):3123-31. PubMed ID: 9671391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53.
    Leiter LM; Chen J; Marathe T; Tanaka M; Dutta A
    Oncogene; 1996 Jun; 12(12):2661-8. PubMed ID: 8700525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 binds to a novel recognition sequence in the proximal promoter of the rat muscle creatine kinase gene and activates its transcription.
    Zhao J; Schmieg FI; Logsdon N; Freedman D; Simmons DT; Molloy GR
    Oncogene; 1996 Jul; 13(2):293-302. PubMed ID: 8710368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 Specifically Binds Triplex DNA In Vitro and in Cells.
    Brázdová M; Tichý V; Helma R; Bažantová P; Polášková A; Krejčí A; Petr M; Navrátilová L; Tichá O; Nejedlý K; Bennink ML; Subramaniam V; Bábková Z; Martínek T; Lexa M; Adámik M
    PLoS One; 2016; 11(12):e0167439. PubMed ID: 27907175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations at position 277 modify the DNA-binding specificity of human p53 in vitro.
    Chène P
    Biochem Biophys Res Commun; 1999 Sep; 263(1):1-5. PubMed ID: 10486243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How p53 binds DNA as a tetramer.
    McLure KG; Lee PW
    EMBO J; 1998 Jun; 17(12):3342-50. PubMed ID: 9628871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probing the functional impact of sequence variation on p53-DNA interactions using a novel microsphere assay for protein-DNA binding with human cell extracts.
    Noureddine MA; Menendez D; Campbell MR; Bandele OJ; Horvath MM; Wang X; Pittman GS; Chorley BN; Resnick MA; Bell DA
    PLoS Genet; 2009 May; 5(5):e1000462. PubMed ID: 19424414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family?
    Bian J; Sun Y
    Proc Natl Acad Sci U S A; 1997 Dec; 94(26):14753-8. PubMed ID: 9405685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor suppressor protein p53 binds preferentially to supercoiled DNA.
    Palecek E; Vlk D; Stanková V; Brázda V; Vojtesek B; Hupp TR; Schaper A; Jovin TM
    Oncogene; 1997 Oct; 15(18):2201-9. PubMed ID: 9393978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of p53 transactivation through high-affinity binding sites.
    Chumakov AM; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription.
    Liu X; Miller CW; Koeffler PH; Berk AJ
    Mol Cell Biol; 1993 Jun; 13(6):3291-300. PubMed ID: 8497252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptional repression by p53 through direct binding to a novel DNA element.
    Johnson RA; Ince TA; Scotto KW
    J Biol Chem; 2001 Jul; 276(29):27716-20. PubMed ID: 11350951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
    Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
    Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.